UK markets closed
  • NIKKEI 225

    27,885.87
    +65.47 (+0.24%)
     
  • HANG SENG

    19,441.18
    -77.11 (-0.40%)
     
  • CRUDE OIL

    74.47
    -2.46 (-3.20%)
     
  • GOLD FUTURES

    1,777.50
    +10.10 (+0.57%)
     
  • DOW

    33,620.52
    -326.58 (-0.96%)
     
  • BTC-GBP

    13,921.59
    -159.57 (-1.13%)
     
  • CMC Crypto 200

    400.06
    -1.74 (-0.43%)
     
  • ^IXIC

    11,049.99
    -189.95 (-1.69%)
     
  • ^FTAS

    4,114.48
    -28.73 (-0.69%)
     

Amryt Reports Q3 2022 Financial and Operational Results

Amryt Pharma plc
Amryt Pharma plc

Amryt Reports Q3 2022 Financial and Operational Results

8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis

11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022

Operating cash flows of $14.3M for Q3 2022

Cash of $83.4M at September 30, 2022

Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY

CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU

Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023

Filsuvez® European launch progressing well

Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4

Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth

Conference call and webcast today at 0830 ET / 1230 GMT

DUBLIN, Ireland, and Boston MA, November 3, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today provides a business update and announces unaudited financial results for the third quarter ended September 30, 2022.

Joe Wiley, CEO of Amryt Pharma, commented: We are pleased to report today’s strong operational and financial results which reflect another excellent quarter for Amryt. These results demonstrate the robust growth we are experiencing and represent our eleventh consecutive quarter of positive EBITDA generation.

Our commercial team delivered a record Mycapssa® quarter with revenue growth of 26.9% QoQ and 292.8% YoY which illustrates the success of the relaunch initiatives we highlighted previously. In Q3, we added an additional 31 new prescribers which brings the YTD total new prescribers to 89, the vast majority of whom are community-based physicians. During the quarter, we also successfully negotiated our first PBM contract with Express Scripts which will greatly simplify the patient access process for Mycapssa®.

Regarding Filsuvez®, the MHRA approved the product for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older in Great Britain.   This follows on from the approval earlier on in the summer of Filsuvez® in the EU. Filsuvez® has now been launched successfully in Europe and we are encouraged by early demand.

Given the strong underlying performance of our business year to date and notwithstanding the significant impact of the strengthening US dollar on our Euro revenues, we are today reaffirming our full year 2022 revenue guidance of $260-$270 million which represents growth of 17%-21% over 2021.

Q3 2022 and Recent Business Highlights:
Metreleptin

  • Metreleptin delivered significant growth in the US with revenues growing by 10.3% YoY in Q3 2022 with patients on therapy in the US now at an all time high

  • Robust EMEA patient demand continued in Q3 and patients on therapy grew by 25.4% YoY, however revenues were impacted by a strong US dollar. Growth on a constant currency basis during Q3 would have been 13.8% YoY.

  • EMEA growth drivers include reimbursement for partial lipodystrophy (PL) in Italy, general lipodystrophy (GL) in the Netherlands and a strong performance in Turkey and the Middle East

  • Reimbursement processes are also being progressed in six other EMEA markets

  • Significant LATAM tender process won and order for $8.3M expected in Q4 revenues

Lomitapide

  • EMEA lomitapide revenues impacted by strong US dollar despite increasing patient numbers

  • Robust EMEA patient demand continued in Q3 and patients on therapy grew by 20.6% YoY. Revenue growth on a constant currency basis during Q3 would have been 11.8% YoY.

  • Performance in Q3 has been strong in all EU countries - driven by Germany, Greece and Spain

  • Recent $6M annualized Saudi Arabia tender awarded with deliveries expected in Q4 2022

Mycapssa®

  • Mycapssa® relaunch progressing well - steady increase in prescriber base with an additional 31 new prescribers added in Q3, 97% of whom were community-based physicians - this brings the YTD total for new prescribers to 89

  • Continued engagement with broad group of endocrinologists during the quarter through in person calls and presence at 11 regional conferences

  • Additional 22 million covered lives for Mycapssa®️, as a result of successful removal from Express Scripts National Formulary Exclusion list effective early September

  • Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023

  • CHMP positive opinion for the use of Mycapssa® in Acromegaly in the EU - European Commission (EC) recommendation is expected on Mycapssa® by end of Q4 2022

  • COMP positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of acromegaly

  • Presented Mycapssa® data from MPOWERED Phase 3 trial at ENEA 2022 meeting

  • Mycapssa® new US patent announced, further strengthening IP portfolio with protection to 2040

  • Received Orphan Drug Designation from the FDA for Mycapssa® for the treatment of carcinoid syndrome associated with neuroendocrine tumors (NET)

Filsuvez®1

  • Filsuvez® launched in Germany in September

  • Good demand since launch - exceeding forecasts in first month

  • Strong inbound interest from other EU countries

  • Expect to begin deliveries to EB patients in other EU countries by end Q4

  • Filsuvez® approved in Great Britain for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older

  • Presented new positive open-label 12-month data analyses from the EASE Phase 3 trial in EB at SPD 2022

  • British Journal of Dermatology published results from EASE Phase 3 Trial in EB

Corporate

  • Stock repurchase program - 294,182 ADSs purchased in Q3 2022 at a weighted average price of $7.43 for a total cost of approx. $2.19M

  • Distribution agreements signed with Farmamondo for markets within the APAC region

  • Legacy Aegerion Corporate Integrity Agreement (CIA) - term of enforcement ended in September 2022

  • FY 2022 revenue guidance of $260M - $270M reaffirmed, representing 17-21% growth over 2021

Q3 2022 Commercial Product Performance:


Q3 2022 (unaudited)

US$’000

US

EMEA

Other

Total

Metreleptin

20,670

16,381

875

37,926

Lomitapide

7,967

6,149

3,069

17,185

Mycapssa®

5,708

-

-

5,708

Filsuvez®

-

27

192

219

Other

-

88

-

88

Total revenue

34,345

22,645

4,136

61,126



Q3 2021 (unaudited)

US$’000

US

EMEA

Other

Total

Metreleptin

18,748

15,618

1,926

36,292

Lomitapide

8,568

6,406

3,565

18,539

Mycapssa®

1,453

-

-

1,453

Filsuvez®

-

-

69

69

Other

-

166

-

166

Total revenue

28,769

22,190

5,560

56,519

  • 8.2% YoY revenue growth in Q3 2022 to $61.1M (Q3 2021: $56.5M); 12.5% YoY revenue growth on a constant currency basis

  • 4.5% increase in metreleptin revenues YoY to $37.9M in Q3 2022 (Q3 2021: $36.3M)

  • US accounted for 54.5% of global metreleptin revenues and EMEA accounted for 43.2% in Q3 2022

  • US metreleptin revenues grew by 10.3% YoY and EMEA metreleptin revenues grew by 4.9% YoY in Q3 2022

  • US accounted for 46.4% of global lomitapide revenues and EMEA accounted for 35.8% in Q3 2022

  • 292.8% increase in Mycapssa® revenues YoY to $5.7M in Q3 2022 (Q3 2021: $1.5M) and 26.9% growth versus Q2 2022

Q3 2022 Financial Highlights:

  • $10.5M operating loss before finance expense for Q3 2022 (Q3 2021: $21.4M operating loss). Excluding non-cash items and share based compensation expenses, this resulted in EBITDA3 of $12.5M.

  • Filsuvez® EMA approval €10.0M ($9.7M) milestone payment paid in Q3 2022

  • Filsuvez® CVR on EMA approval of $5.7M paid in Q3 2022

  • Cash of $83.4M at September 30, 2022 (June 30, 2022: $90.7M). Excluding the impact of the EMA milestone payment and CVR, cash would have increased to $98.8M at September 30, 2022.

  • The strengthening US dollar impacts Euro denominated revenues but has a negligible effect on EBITDA given the natural hedge created by Euro denominated costs

IFRS and non-GAAP adjusted Q3 2022 results:

US$M

Q3 2021
(unaudited)

 

Q3 2022
(unaudited)

Q3 2022
Non-cash adjustments2

Q3 2022 Non-GAAP Adjusted

Revenue

56.5

61.1

-

61.1

Gross profit

29.3

27.4

19.7

47.1

R&D expenses

(11.0)

(8.0)

-

(8.0)

SG&A expenses

(25.7)

(27.0)

0.4

(26.6)

Restructuring and acquisition costs

(11.3)

-

-

-

Share based compensation expenses

(2.7)

(2.9)

2.9

-

Operating (loss) / profit before finance expense

(21.4)

(10.5)

23.0

12.53

 

Operating (loss) / profit before finance expense and restructuring and acquisition costs

(10.1)

(10.5)

23.0

12.53

1  Filsuvez® (birch extract) gel (“Filsuvez®”) has been selected as the brand name for Oleogel-S10. Filsuvez® is approved in the EU and Great Britain for the treatment of partial thickness wounds associated with junctional and dystrophic Epidermolysis Bullosa in patients 6 months and older.

2  Non-cash items include amortisation of the acquired metreleptin, lomitapide, Mycapssa® and Filsuvez® intangible assets ($16.6M), amortisation of the inventory fair value step-up related to the acquisition of Chiasma, Inc. ($3.1M), depreciation and amortisation ($0.4M) and share based compensation expenses ($2.9M).

3  EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

Filsuvez® Regulatory Update:
In June and September respectively, Amryt announced the European Commission (EC) and UK Medical Healthcare & Products Regulatory Agency (MHRA) approval of Filsuvez® in the European Union (EU) and Great Britain for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare and distressing genetic skin disorder affecting young children and adults for which, until now, there has been no approved treatment in any market.

The EC and MHRA approvals of Filsuvez® are supported by Phase 3 data from the EASE trial which was the largest ever global trial conducted in patients with EB, performed across 58 sites in 28 countries.

As previously announced, Amryt plans to proceed to the Formal Dispute Resolution pathway with the FDA’s Center for Drug Evaluation and Research (CDER) by which NDA applicants can seek to resolve scientific and/or medical disputes that cannot be resolved at the division level. The Company expects to submit the formal dispute resolution in November 2022.

Guidance & Outlook:
Given the continued strong performance of the Company’s commercial products and notwithstanding the impact of the strengthening US dollar on the Company’s Euro denominated revenues, the board is today reaffirming revenue guidance for FY 2022 in the range of $260M - $270M which represents growth of 17% to 21% on FY 2021.

Conference Call & Webcast:
Amryt will host a conference call and webcast for analysts and investors today at 0830 ET/1230 GMT.

Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj

Telephone Dial in details:

Standard International Number

+ 39 (0) 02 802 0911

United States

+1 718 705 8796

United Kingdom

+44 (0) 1212 818004

Ireland

+353 (1) 526 9444

A playback facility will be available from November 3, 2022 - November 10, 2022. Access details for the playback facility are as follows: Dial +39 02 802 0987 then press 700723# and 723#.

About Amryt
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryt’s commercial business comprises four orphan disease products – metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); lomitapide (Juxtapid®/ Lojuxta®); and Oleogel-S10 (Filsuvez®).

Myalept®/Myalepta® (metreleptin) is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this link.

Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approved by the FDA. Mycapssa® has also been submitted to the EMA and has received a positive opinion by the CHMP recommending the approval of Mycapssa® in the European Union (EU). For additional information, please follow this link.

Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel, Saudi Arabia and Brazil (under the trade name Lojuxta®). For additional information, please follow this link.

Filsuvez® (Oleogel-S10) is approved in the EU and Great Britain for the treatment of partial thickness wounds associated with junctional and dystrophic Epidermolysis Bullosa in patients 6 months and older.

Amryt’s pre-clinical gene therapy candidate, AP103, offers a potential treatment for patients with Dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders.

For more information on Amryt, including products, please visit www.amrytpharma.com.

Forward-Looking Statements
This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management.

Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com
Tim McCarthy, LifeSci Advisors, LLC, +1 (917) 679 9282, tim@lifesciadvisors.com

Amryt Pharma plc
Condensed Consolidated Statement of Comprehensive Loss

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

Note

 

2022

(unaudited)

 

2021

(unaudited)

 

2022

(unaudited)

 

2021

(unaudited)

 

 

 

US$’000

 

US$’000

 

US$’000

 

US$’000

Revenue

3

 

61,126

 

56,519

 

188,791

 

167,713

Cost of product sales

 

 

(14,036)

 

(14,127)

 

(45,502)

 

(41,108)

Amortization of acquired intangibles

 

 

(16,593)

 

(12,701)

 

(45,490)

 

(34,184)

Inventory fair value step-up

 

 

(3,074)

 

(437)

 

(6,850)

 

(1,641)

Total of cost of sales

 

 

(33,703)

 

(27,265)

 

(97,842)

 

(76,933)

Gross profit

 

 

27,423

 

29,254

 

90,949

 

90,780

Research and development expenses

 

 

(8,005)

 

(11,000)

 

(28,556)

 

(28,454)

Selling, general and administrative expenses

 

 

(26,976)

 

(25,706)

 

(82,918)

 

(62,438)

Restructuring and acquisition costs

5

 

(9)

 

(11,226)

 

(676)

 

(14,679)

Share based payment expenses

4

 

(2,902)

 

(2,689)

 

(8,930)

 

(5,905)

Operating loss before finance expense

 

 

(10,469)

 

(21,367)

 

(30,131)

 

(20,696)

Non-cash change in fair value of contingent consideration

5

 

(771)

 

(3,030)

 

3,522

 

(8,897)

Non-cash contingent value rights (loss)/gain

5

 

(504)

 

(1,915)

 

781

 

(5,515)

Net finance expense – other

 

 

(6,356)

 

(6,424)

 

(24,243)

 

(20,163)

Loss on ordinary activities before taxation

 

 

(18,100)

 

(32,736)

 

(50,071)

 

(55,271)

Tax (charge)/credit on loss on ordinary activities

 

 

(2,695)

 

15,527

 

7,736

 

14,726

Loss for the period attributable to the equity holders of the Company

 

 

(20,795)

 

(17,209)

 

(42,335)

 

(40,545)

Exchange translation differences which may be reclassified through profit or loss

 

 

(14)

 

240

 

(383)

 

2,583

Total other comprehensive (loss)/income

 

 

(14)

 

240

 

(383)

 

2,583

Total comprehensive loss for the period attributable to the equity holders of the Company

 

 

(20,809)

 

(16,969)

 

(42,718)

 

(37,962)

 

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

 

 

Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (US$)

6

 

(0.06)

 

(0.07)

 

(0.13)

 

(0.20)

Amryt Pharma plc
Condensed Consolidated Statement of Financial Position

 

 

 

As at,

 

Note

 

September 30,

2022

(unaudited)

 

December 31, 2021

(restated*)

 

 

 

US$’000

 

US$’000

Assets

 

 

 

 

 

Non-current assets

 

 

 

 

 

Goodwill

7

 

54,124

 

54,124

Intangible assets

7

 

449,816

 

503,330

Property, plant and equipment

 

 

6,738

 

7,416

Other non-current assets

 

 

1,749

 

1,885

Total non-current assets

 

 

512,427

 

566,755

Current assets

 

 

 

 

 

Trade and other receivables

8

 

50,810

 

53,908

Inventories

9

 

90,238

 

81,835

Cash and cash equivalents, including restricted cash

10

 

83,400

 

113,032

Total current assets

 

 

224,448

 

248,775

Total assets

 

 

736,875

 

815,530

 

 

 

 

 

 

Equity and liabilities

 

 

 

 

 

Equity attributable to owners of the parent

 

 

 

 

 

Share capital

11

 

25,561

 

25,500

Share premium

11

 

322,982

 

318,153

Other reserves

11

 

247,122

 

246,303

Accumulated deficit

 

 

(271,388)

 

(231,194)

Total equity

 

 

324,277

 

358,762

Non-current liabilities

 

 

 

 

 

Contingent consideration and contingent value rights

5

 

51,820

 

81,113

Deferred tax liability

 

 

5,809

 

15,144

Long term loan

12

 

98,945

 

93,395

Convertible notes

13

 

109,655

 

105,788

Provisions and other liabilities

14

 

3,225

 

4,049

Total non-current liabilities

 

 

269,454

 

299,489

Current liabilities

 

 

 

 

 

Trade and other payables

 

 

134,947

 

149,734

Provisions and other liabilities

14

 

6,966

 

7,545

Contingent consideration

5

 

1,231

 

Total current liabilities

 

 

143,144

 

157,279

Total liabilities

 

 

412,598

 

456,768

Total equity and liabilities

 

 

736,875

 

815,530

*see Note 16

Amryt Pharma plc
Condensed Consolidated Statement of Cash Flows

 

Nine months ended September 30,

 

Note

 

2022

(unaudited)

 

2021

(unaudited)

 

 

 

US$’000

 

US$’000

Cash flows from operating activities

 

 

 

 

 

Loss on ordinary activities after taxation

 

 

(42,335)

 

(40,545)

Net finance expense - other

 

 

24,243

 

20,163

Depreciation and amortization

 

 

46,672

 

35,238

Amortization of inventory fair value step-up

 

 

6,850

 

1,641

Share based payment expenses

4

 

8,930

 

5,905

Non-cash change in fair value of contingent consideration

5

 

(3,522)

 

8,897

Non-cash contingent value rights (loss)/gain

5

 

(781)

 

5,515

Deferred taxation credit

 

 

(9,335)

 

(15,677)

Movements in working capital and other adjustments:

 

 

 

 

 

Change in trade and other receivables

8

 

3,287

 

(2,609)

Change in trade and other payables

 

 

(17,205)

 

(108,468)

Change in provision and other liabilities

14

 

(848)

 

(2,756)

Change in inventories

 

 

(15,253)

 

39

Change in non-current assets

 

 

136

 

763

Net cash flow from/(used in) operating activities

 

 

839

 

(91,894)

 

 

 

 

 

 

Cash flow from investing activities

 

 

 

 

 

Net cash received on acquisition of subsidiary

 

 

 

107,942

Milestone payments for contingent consideration and contingent value rights

 

 

(16,208)

 

Payments for property, plant and equipment

 

 

(892)

 

(92)

Payments for intangible assets

 

 

(109)

 

(830)

Deposit interest received

 

 

135

 

3

Net cash flow used in investing activities

 

 

(17,074)

 

107,023

 

 

 

 

 

 

Cash flow from financing activities

 

 

 

 

 

Net proceeds/(costs) from issue of equity instruments

 

 

1,311

 

(116)

Payments for share repurchases under Share buyback program

 

 

(2,197)

 

Proceeds from long term borrowings - net of debt issue costs

 

 

98,344

 

Repayment of long term debt

 

 

(98,761)

 

Interest paid

 

 

(8,997)

 

(7,597)

Payment of leases

 

 

(912)

 

(789)

Net cash flow used in financing activities

 

 

(11,212)

 

(8,502)

 

 

 

 

 

 

Exchange and other movements

 

 

(2,185)

 

(2,248)

 

 

 

 

 

 

Net change in cash and cash equivalents

 

 

(29,632)

 

4,379

Cash and cash equivalents at beginning of the period

 

 

113,032

 

118,798

Restricted cash at end of the period

10

 

150

 

50

Cash at bank available on demand at end of the period

10

 

83,250

 

123,127

Total cash and cash equivalents at end of the period

10

 

83,400

 

123,177

Amryt Pharma plc
Condensed Consolidated Statement of Changes in Equity
For the period ended September 30, 2022

 

Note

 

Share

capital

 

Share

premium

 

Treasury

shares

 

Share

based

payment

reserve

 

Merger

reserve

 

Reverse

acquisition

reserve

 

Equity

component

of convertible

notes

 

Other

distributable

reserves

 

Currency

translation

reserve

 

Accumulated

deficit

 

Total

 

 

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

Balance at January 1, 2022 as restated*

 

 

25,500

 

318,153

 

 

20,593

 

42,627

 

(73,914)

 

29,210

 

217,634

 

10,153

 

(231,194)

 

358,762

Loss for the period

 

 

 

 

 

 

 

 

 

 

 

(42,335)

 

(42,335)

Foreign exchange translation reserve

 

 

 

 

 

 

 

 

 

 

(383)

 

 

(383)

Total comprehensive loss

 

 

 

 

 

 

 

 

 

 

(383)

 

(42,335)

 

(42,718)

Transactions with owners

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issue of shares for share options exercised and vesting of RSUs

11

 

120

 

6,535

 

 

(5,155)

 

 

 

 

 

 

 

1,500

Shares repurchased from Share buyback

11

 

(59)

 

(1,706)

 

(432)

 

 

 

 

 

 

 

 

(2,197)

Share based payment expense

4

 

 

 

 

8,930

 

 

 

 

 

 

 

8,930

Share based payment expense – Lapsed

 

 

 

 

 

(2,141)

 

 

 

 

 

 

2,141

 

Total transactions with owners

 

 

61

 

4,829

 

(432)

 

1,634

 

 

 

 

 

 

2,141

 

8,233

Balance at September 30, 2022 (unaudited)

 

 

25,561

 

322,982

 

(432)

 

22,227

 

42,627

 

(73,914)

 

29,210

 

217,634

 

9,770

 

(271,388)

 

324,277

* see Note 16

For the period ended September 30, 2021

 

Note

 

Share

capital

 

Share

premium

 

Warrant

reserve

 

Treasury

shares

 

Share

based

payment

reserve

 

Merger

reserve

 

Reverse

acquisition

reserve

 

Equity

component

of convertible

notes

 

Other

distributable

reserves

 

Currency

translation

reserve

 

Accumulated

deficit

 

Total

 

 

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

 

US$’000

Balance at January 1, 2021 (audited)

 

 

13,851

 

51,408

 

14,762

 

(7,421)

 

7,860

 

42,627

 

(73,914)

 

29,210

 

217,634

 

5,730

 

(235,605)

 

66,142

Loss for the period

 

 

 

 

 

 

 

 

 

 

 

 

(40,545)

 

(40,545)

Foreign exchange translation reserve

 

 

 

 

 

 

 

 

 

 

 

2,583

 

 

2,583

Total comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

2,583

 

(40,545)

 

(37,962)

Transactions with owners

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issue of treasury shares in exchange for warrants

11

 

23

 

99

 

 

439

 

 

 

 

 

 

 

 

561

Issue of treasury shares for share options exercised

11

 

25

 

89

 

 

465

 

(191)

 

 

 

 

 

 

 

388

Issue of shares and treasury shares in exchange for warrants

11

 

749

 

7,496

 

(14,762)

 

6,517

 

 

 

 

 

 

 

 

Issue of shares in consideration of Chiasma acquisition

5

 

10,547

 

249,789

 

 

 

 

 

 

 

 

 

 

260,336

Share based payment reserve recognized on Chiasma acquisition

11

 

 

 

 

 

10,157

 

 

 

 

 

 

 

10,157

Issue of shares for share options exercised and vesting of RSUs

11

 

66

 

1,897

 

 

 

(1,467)

 

 

 

 

 

 

 

496

Share based payment expense

4

 

 

 

 

 

5,905

 

 

 

 

 

 

 

5,905

Share based payment expense - Lapsed

 

 

 

 

 

 

(54)

 

 

 

 

 

 

54

 

Total transactions with owners

 

 

11,410

 

259,370

 

(14,762)

 

7,421

 

14,350

 

 

 

 

 

 

54

 

277,843

Balance at September 30, 2021 (unaudited)

 

 

25,261

 

310,778

 

 

 

22,210

 

42,627

 

(73,914)

 

29,210

 

217,634

 

8,313

 

(276,096)

 

306,023

1. General information

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

As used herein, references to ‘‘we,’’ ‘‘us,’’ ‘‘Amryt’’ or the ‘‘Group’’ in these condensed consolidated interim financial statements shall mean Amryt Pharma plc and its global subsidiaries, collectively. References to the ‘‘Company’’ in these condensed consolidated interim financial statements shall mean Amryt Pharma plc.

Amryt Pharma plc is a company incorporated in England and Wales. The Company is listed on Nasdaq (ticker: AMYT). The Company was also listed on the AIM market of the London Stock Exchange (ticker: AMYT) up until January 11, 2022, on which date the Company completed the cancellation its admission to AIM. The cancellation was announced by the Company on November 22, 2021, and following the AIM delisting, the Company’s American Depositary Shares (“ADSs”) remain listed, and will only be tradeable, on Nasdaq. The Company’s last day of trading on AIM was January 10, 2022.

Amryt acquired Chiasma, Inc. (“Chiasma”) in August 2021. The combined company will be a global leader in rare and orphan diseases with four on-market commercial products, a global commercial and operational footprint and a significant development pipeline of therapies with the financial flexibility to execute its growth plans. Amryt’s commercial business comprises four orphan disease products – metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); lomitapide (Juxtapid®/ Lojuxta®); and Oleogel-S10 (Filsuvez®).

Filsuvez® (Oleogel-S10) is approved in the EU and Great Britain for the treatment of partial thickness wounds associated with junctional and dystrophic Epidermolysis Bullosa in patients 6 months and older.

During Q2 2022, Amryt had a Type A meeting with the FDA to discuss the issues raised in the Complete Response Letter (CRL) received in February 2022 relating to Amryt’s New Drug Application (NDA) for Oleogel-S10. Following this meeting, Amryt is proceeding to the Formal Dispute Resolution pathway in the FDA’s Center for Drug Evaluation and Research (CDER) by which NDA applicants can seek to resolve scientific and/or medical disputes that cannot be resolved at the division level. The Company expects to submit the formal dispute resolution in November.

2. Accounting policies

Basis of preparation

The condensed consolidated interim financial statements of the Group have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all the information required in annual financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) and should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2021. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the Group’s financial position and performance since the last annual financial statements. The accounting policies used in the preparation of the interim financial information are the same as those used in the Group’s audited financial statements for the year ended December 31, 2021, and those which are expected to be used in the financial statements for the year ended December 31, 2022.

Results for the nine-month period ended September 30, 2022, are not necessarily indicative of the results that may be expected for the financial year ending December 31, 2022.

Basis of going concern

Having considered the Group’s current financial position and cash flow projections, the Board of Directors believes that the Group will be able to continue in operational existence for at least the next 12 months from the date of approval of these condensed consolidated interim financial statements and that it is appropriate to continue to prepare the condensed consolidated interim financial statements on a going concern basis.

As part of their inquiries, the Board of Directors reviewed budgets, projected cash flows, and other relevant information for a period not less than 12 months from the date of approval of the condensed consolidated interim financial statements for the period ended September 30, 2022.

Basis of consolidation

The condensed consolidated interim financial statements comprise the financial statements of the Group for the period ended September 30, 2022. Subsidiaries are entities controlled by the Company. Where the Company has control over an investee, it is classified as a subsidiary. The Company controls an investee if all three of the following elements are present: power over an investee, exposure or rights to variable returns from its involvement with the investee and the ability to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control.

Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Intergroup balances and any unrealized gains or losses, income or expenses arising from intergroup transactions are eliminated in preparing the condensed consolidated interim financial statements.

Presentation of balances

The condensed consolidated interim financial statements are presented in U.S. dollars (‘‘US$’’), rounded to the nearest thousand, which is the functional currency of the Company and presentation currency of the Group.

The following table discloses the major exchange rates of those currencies other than the functional currency of US$ that are utilized by the Group:

Foreign currency units to 1 US$

 

£

 

ILS

 

NOK

 

DKK

Average three-month period to September 30, 2022 (unaudited)

0.9919

 

0.8496

 

3.3994

 

9.9752

 

7.3795

Average nine-month period to September 30, 2022 (unaudited)

0.9403

 

0.7966

 

3.3118

 

9.4089

 

6.9958

At September 30, 2022 (unaudited)

1.0275

 

0.9148

 

3.5461

 

10.7479

 

7.6414


Foreign currency units to 1 US$

 

£

 

ILS

 

NOK

 

DKK

Average period to December 31, 2021 (audited)

0.8454

 

0.7271

 

3.2322

 

8.5975

 

6.2875

At December 31, 2021 (audited)

0.8830

 

0.7413

 

3.1115

 

8.8074

 

6.5664


Foreign currency units to 1 US$

 

£

 

ILS

 

NOK

 

DKK

Average three-month period to September 30, 2021 (unaudited)

0.8479

 

0.7252

 

3.2342

 

8.7609

 

6.3057

Average nine-month period to September 30, 2021 (unaudited)

0.8358

 

0.7221

 

3.2573

 

8.5522

 

6.2158

At September 30, 2021 (unaudited)

0.8589

 

0.7417

 

3.2149

 

8.7140

 

6.3870

(€ = Euro; £ = Pounds Sterling, ILS = Israeli Shekel, NOK = Norwegian Kroner, DKK = Danish Kroner)

Changes in accounting policies and disclosures

There are no new standards and amendments to IFRS effective as of January 1, 2022, that are relevant to the Group.

Critical accounting judgements and key sources of estimation uncertainty

In preparing these condensed consolidated interim financial statements in conformity with IFRS management is required to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the condensed consolidated interim financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

The significant estimates, assumptions or judgements, applied in the condensed consolidated interim financial statements were the same as those applied in the Group’s audited financial statements for the year ended December 31, 2021.

Principal accounting policies

The condensed consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the Group’s audited financial statements for the year ended December 31, 2021.

3. Segment information

The Group is a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases.

The Group currently operates as one business segment, pharmaceuticals, and is focused on the development and commercialization of four commercial products and a number of development products. The Group derives its revenues primarily from one source, being the pharmaceutical sector with high unmet medical need.

The Group’s Chief Executive Officer, Joseph Wiley, is currently the Company’s chief operating decision maker (‘‘CODM’’). The Group does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Group does not accumulate discrete financial information with respect to separate service lines and does not have separate reportable segments. The following table summarizes total revenues from external customers by product and by geographic region, based on the location of the customer.

 

Three months ended September 30, 2022 (unaudited)

 

U.S.

 

EMEA

 

Other

 

Total

 

US$’000

 

US$’000

 

US$’000

 

US$’000

Metreleptin

20,670

 

16,381

 

875

 

37,926

Lomitapide

7,967

 

6,149

 

3,069

 

17,185

Mycapssa®

5,708

 

 

 

5,708

Filsuvez®

 

27

 

192

 

219

Other

 

88

 

 

88

Total revenue

34,345

 

22,645

 

4,136

 

61,126


 

Three months ended September 30, 2021 (unaudited)

 

U.S.

 

EMEA

 

Other

 

Total

 

US$’000

 

US$’000

 

US$’000

 

US$’000

Metreleptin

18,748

 

15,618

 

1,927

 

36,293

Lomitapide

8,568

 

6,406

 

3,564

 

18,538

Mycapssa®

1,453

 

 

 

1,453

Filsuvez®

 

 

69

 

69

Other

 

166